PRECISION MEDICINE GENERATED IN-SITU

Cuttlefish Bio is overcoming the fundamental toxicity limitations of Antibody-Drug Conjugates (ADCs). While traditional ADCs often suffer from high systemic toxicity, with over 99% of the conjugate turned over in healthy tissue, our Antibody-Directed Enzyme Prodrug Therapy (ADEPT) platform changes the equation.

Instead of carrying a toxic payload through the bloodstream, we use a two-step approach.

THE TWO-STEP ADEPT PROCESS

STEP 1:

Pre-Targeting

Administration:

A highly specific antibody-directed enzyme (ADE) is delivered into the bloodstream.

Loading:

The antibody portion of the ADE binds to specific tumor antigens and accumulates in the tumor microenvironment.

Result:

The tumor is now "primed" with a local enzyme factory, while the rest of the body remains unaffected because the enzyme itself is non-toxic.

STEP 2:

Prodrug Administration

Administration:

A non-toxic prodrug is administered separately.

Systemic Safety:

Because the prodrug is inactive, it circulates through healthy tissue without causing the systemic toxicity associated with traditional ADCs.

In-Situ Activation:

When the prodrug reaches the tumour, the "docked" enzymes convert it into a potent, cell-killing payload exactly where it is needed.

Bystander Effect:

The resulting small-molecule payload diffuses through the tumor microenvironment, killing neighboring cells regardless of whether they express the target antigen.

WHY THIS SOLVES THE TOXICITY PROBLEM

Traditional ADCs carry the toxic payload through the entire body, leading to over 99% of the drug being turned over in healthy tissue. By contrast, Cuttlefish Bio's ADEPT platform ensures the payload is delivered once the components meet at the tumor site.